Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2023. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
For more information, please contact us.
Tuesday, March 21, 2023| 1–3pm CT
- Delivering Patient-Centered, Equitable Care in Anemia of CKD: Expert Insights on Translating Progress to Practice to Minimize Burden of Disease and Healthcare Disparities| Location: 303BC
-
- Provider ProCE
- Supported by GSK
- Continuing education credit available for this activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with anemia of CKD, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
- Contact hours: 1.5
Program Description
CKD affects an estimated 15% of US adults. Anemia often develops in the early stages of CKD and typically worsens as kidney function declines and affects nearly all patients who require dialysis. The current cornerstone of anemia treatment in CKD includes drugs that are erythropoietin analogs and those that stimulate erythropoiesis, which together can be described as erythropoiesis-stimulating agents (ESAs). Other treatments include oral or IV iron supplements, transfusions of red blood cells, and dietary changes. Despite being the mainstay of therapy, ESAs and iron are not without their limitations due to safety concerns, the route of administration, and cost. The unmet medical need for more convenient, efficacious, or safer alternatives has led to research in agents with novel mechanisms of action. The clinical potential of targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors is an emerging treatment strategy for anemia associated with CKD. These drugs have an ability to inhibit and reduce hepcidin levels. HIF-PH inhibitors stimulate endogenous EPO production and enhance serum iron availability. These oral agents appear to be capable of replacing the injection of ESAs and minimizing the need for IV iron therapy as demonstrated in clinical trials in CKD-related anemia. Numerous HIF-PH inhibitors are currently under development. Disparities in healthcare are pervasive and have continued to plague the healthcare system despite increasing recognition of their existence. Unfortunately, striking racial and ethnic differences are prevalent in CKD. Compared with white patients, anemia is more prevalent and severe among Black Americans at every stage of CKD. These disparities are due in part to the lack of appropriate treatment that underserved populations receive. Considering that people of color and ethnic groups carry a disproportionate burden of anemia of CKD, HCPs must have increased awareness and knowledge of optimal management strategies for these vulnerable patient populations.
Learning Objectives
- Discuss the underrecognition and undertreatment of anemia in patients with CKD and the subsequent burden of disease
- Recognize the pathophysiology of anemia of CKD
- Evaluate clinical trial data on the physiologic actions, efficacy, and safety of HIF-PH inhibitors and their potential role in the management of anemia of CKD
- Incorporate health disparity mitigation strategies into the care of patients with anemia of CKD
Program Manager
Kerry Rosa
ProCE
krosa@practicingclinicians.com - New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes| Location: 304BC
-
- Provider: Pharmacy Times Continuing Education™
- This educational activity is supported by educational grants from GlaxoSmithKline, Incyte Corporation, and Bristol Myers Squibb.
- Continuing education credit available for managed care pharmacists
- Contact hours: 1.5
Program Description
Advances in Janus-associated kinase (JAK) inhibitors have offered patients with myelofibrosis (MF) additional treatment options. However, current therapies do not address all aspects of MF, and their use can be limited by adverse effects as well as some patients developing resistance. Patients with MF experience frequent symptoms that impact overall quality of life; investigational agents that target gene signaling pathways offer a therapeutic option that has the potential to minimize impact of the disease. Treatments for MF vary based on primary or secondary disease as well as individual patient risk status. Managed care pharmacists should be informed of guideline recommendations, standard therapies, and strategies for ongoing assessment of disease to continually evaluate therapies for efficacy and toxicity. This program will review treatment of MF with approved JAK inhibitors and examine efficacy and safety data for emerging gene therapies. Expert faculty will also share cost considerations for managed care professionals involved in the management of patients with MF. Formulary development and approaches to optimize stepwise therapy to delay disease progression in patients with MF will also be discussed.
Learning Objectives
- Explore the disease burden associated with myelofibrosis (MF), including assessment of patient risk factors and comorbidities that affect treatment and outcomes.
- Examine the impact of JAK/STAT and other molecular pathways that contribute to disease progression, and the treatment goals for the management of MF.
- Analyze the recent updates in clinical data for JAK inhibitors and targeted therapies under investigation for the management of MF.
- Illustrate the direct and indirect costs in the management of MF and identify best practices to facilitate appropriate use of new and emerging therapeutic options to improve outcomes in this population.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.comRegistration Link:
https://event.pharmacytimes.org/event/0fa6b151-ca92-4bf7-8cf5-3f22255e33cf/summary?tm=8abR3rC2SRixheWG5WvU53hofKfSJceAu4Xo_HuB0TY&locale=en-US
Tuesday, March 21, 2023| 6–8pm CT
- Enhancing the Value of Endometrial Cancer Care With Immunotherapy Regimens: A Managed Care Mindset | Location: 304BC
-
- Provider Medscape Education
- Supported by GlaxoSmithKline
- Continuing education credit available for Pharmacists
- Contact hours: 1.5
Program Description
The proposed 90-minute CPE-certified live/livestreamed symposium will present a comprehensive review of the recent updates related to the evolving role of immunotherapy in advanced EC. The symposium will feature a lively and engaging format in which 3 expert panelists will offer their scientific expertise on selected topics. There will be a focus on the evidence-based aspects of advanced EC care, a focus on the practical aspects of EC and a review of roles and responsibilities of clinical pharmacists in the management of patients with advanced EC. o Faculty will introduce patient case scenarios that will help put presented information into practice, thereby facilitating provision of patient-centered, evidence-based, and value-based care.
Learning Objectives
- Increased knowledge regarding the o Clinical data associated with immunotherapies in patients with advanced EC
- Pharmacoeconomic data for immunotherapies for treatment of patients with advanced EC
- Greater competence related to implementation of clinical pathways with immunotherapies for improved patient outcomes
- Greater confidence in their ability to improve patient adherence through managed care and clinical pharmacy approaches
Program Manager
Kelly Connors
Medscape Education
kconnors@medscapelive.comRegistration Link:
- NASH: An Epidemic with Enormous Health and Economic Implications| Location: 303BC
-
- Provider Prova Education
- Supported by Madrigal Pharmaceuticals
- Continuing education credit available for pharmacists, physicians, physician assistants, nurse practitioners, and nurses.
- Contact hours: 1.5
Program Description
Can you make it to the top of our NASH leaderboard? Join us for a satellite symposium on the nonalcoholic steatohepatitis (NASH) epidemic and put your skills to the test! Using a novel gamified approach, you’ll compete with your peers while learning about the complex disease state and economic burden of NASH. Don’t miss this opportunity to hear from multiple experts in the field and find out how you measure up!
Learning Objectives
- Explain the benefit of early diagnosis and risk stratification for health outcomes in patients with nonalcoholic fatty liver disease (NAFLD)
- Summarize the health and economic impacts of nonalcoholic steatohepatitis (NASH)
- Differentiate between treatment of NAFLD and treatment of NASH
- Identify the FDA-defined efficacy endpoint of investigational treatments of NASH
Program Manager
Kate Nagele
Global Learning Collaborative
info@provaeducation.comRegistration Link:
In-person: CME - NASH: An Epidemic with Enormous Health and Economic Implications - ReachMD
Live broadcast: CME - NASH: An Epidemic with Enormous Health and Economic Implications - ReachMD
Wednesday, March 22, 2023| 6–8am CT
- Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care| Location: 303BC
-
- Provider statement: Provided by ProCE, LLC
- Supporter statement: Supported by educational grants from AstraZeneca, GSK, Immunogen, Inc., Merck Sharp & Dohme LC, and Novocure, Inc.
- Credit type: ACPE credit (Pharmacist)
- Target audience: pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with ovarian cancer, and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care
- This activity is approved for 1.5 contact hours
- This activity is provided at no cost to participants
Program Description
The landscape of ovarian cancer care continues to evolve with emerging long-term survival data, society and guideline updates, and changes to FDA approved indications for poly (ADP-ribose) polymerase (PARP) inhibitors. Recent approval of mirvetuximab soravtansine, an antibody-drug conjugate targeting the folate receptor, also has expanded the available treatment options for patients with primary platinum refractory or platinum resistant disease. Moreover, emerging therapies under clinical investigation such as immune checkpoint inhibitors, and tumor treating fields in combination with platinum chemotherapy represent new hope for women with ovarian cancer. Despite all of these exciting advances, underrepresented patients of color disproportionally face barriers to optimal treatment for ovarian cancer, such as access to care, lack of awareness of treatment options, inconsistency in the quality of care received, and mistrust of medical professionals. Data also suggest that many providers are unaware of these disparities in their fields. Recognition and awareness of factors contributing to inequities is an important first step in improving care, and healthcare professionals must work to educate all members of the multidisciplinary healthcare team, including pharmacists and managed care professionals, to help address these barriers to care. As health disparities often involve medication-related concerns (eg, access, cost, adherence) managed care pharmacy professionals can and should urgently address these concerns. It is critical that pharmacists, including managed care professionals, are aware of healthcare disparities in ovarian cancer care and are provided with strategies that will promote optimal and equitable clinical integration of approved and emerging therapies for patients with ovarian cancer.Join us for this exciting live ACPE-certified presentation to hear from clinical and managed care pharmacists on how to improve health equity for patients with ovarian cancer, including a chance to have your questions answered by the experts.
Learning Objectives
- Evaluate current and emerging data on PARP inhibitors as single agents or in combination therapies for ovarian cancer
- Determine individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed ovarian cancer that incorporate novel therapies and combination strategies
- Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
- Identify strategies to promote optimal and equitable clinical integration of approved and emerging therapies for patients with ovarian cancer to reduce associated costs, minimize healthcare disparities, and improve outcomes for patients
Program Manager
Kerry Rosa
ProCE
krosa@practicingclinicians.comProgram Faculty
Colleen Bohnenkamp, PharmD, BCOP, BCPS
Oncology Clinical Pharmacist
University of Kansas Health System Bloch Cancer Center
Kansas City, KansasLaura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Plantation, Florida - Managing More Than the Disease: Improving the Entire Care Journey for Patients With aTTP| Location: 304BC
-
- Provider statement: Provided by Medscape Education
- Supporter statement: Supported by Sanofi
- Credit type: ACPE credit (Pharmacist)
- This activity is approved for 1.5 contact hours
Program Description
The same 90-minute hybrid symposium will be held at each pharmacist-focused conference, providing both virtual and in-person audiences the opportunity to interact with 3 faculty experts (2 pharmacists, 1 hematologist) about advances in the management of aTTP. Including dual faculty chairs (each focused on either the live or online audience) ensures all attendees experience an educational event tailored to their venue.Learning Objectives
- As a result of participating in this activity, the learner will have increased knowledge regarding the clinical evidence evaluating treatment options for aTTP.
- As a result of participating in this activity, the learner will have greater competence related to utilizing biomarkers for aTTP disease monitoring.
- As a result of participating in this activity, the learner will have greater competence related to communicating treatment considerations for patients receiving therapy for aTTP as part of the interprofessional team.
- As a result of participating in this activity, the learner will have greater confidence in their ability to leverage the role of the pharmacist to maximize outcomes for patients with aTTP.
Program Manager
Kelly Connors
Medscape Education
kconnors@medscapelive.comRegistration Link:
Home (eventscloud.com)
Wednesday, March 22, 2023| 11:30am–1:30pm CT
- Discussions on Recent Data and Best Practices for Managed Care in the Treatment of nAMD and DME| Location: 303BC
-
- Provider: Pharmacy Times Continuing Education™
- This activity is supported by an educational grant from Genentech, a member of the Roche Group.
- Continuing education credit available for managed care pharmacists
- Contact hours: 1.5
Program Description
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are 2 leading causes of vision loss among adults worldwide, affecting over 40 million people globally. Intravitreal anti-vascular endothelial growth factor (anti-VGEF) therapies have been the gold standard for the treatment of nAMD and DME to reduce the rates of vision loss through the prevention of the growth of new blood vessels. However, adverse effects and the burden of frequent injections due to undesirable treatment durability often leads to poorer real-world outcomes compared with what is seen in clinical trials. Managed care professionals must be able to identify gaps in patients’ treatment and consider evidence supporting recent advancements in therapies in order to optimize patient outcomes while providing cost-effective care. This activity will review recent data on the advances in nAMD and DME treatment in addition to best practices in applying the clinical data to managed care considerations. This expert panel discussion will highlight the burden of the diseases and treatments and discuss a patient’s journey through various treatment strategies utilizing patient cases.
Learning Objectives
- Expose the disease burden and limitations of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
- Explore the recent updates on the efficacy and safety of available treatment approaches for nAMD and DME to close the gaps in care
- Apply the best practices for managed care professionals to incorporate the latest data and advances in treatment to improve outcomes for patients with nAMD and DME
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.comRegistration Link:
https://event.pharmacytimes.org/event/0fa6b151-ca92-4bf7-8cf5-3f22255e33cf/summary?tm=8abR3rC2SRixheWG5WvU53hofKfSJceAu4Xo_HuB0TY&locale=en-US - Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma| Location: 304BC
-
- Provider: Pharmacy Times Continuing Education™
- This activity is supported by educational grants from GlaxoSmithKline and Regeneron Pharmaceuticals, Inc.
- Continuing education credit available for managed care pharmacists
- Contact hours: 1.5
Program Description
B-cell maturation antigen (BCMA) has emerged as a therapeutic target in multiple myeloma (MM) as patients with overexpression and activation of BCMA are at risk of disease progression. Drugs targeting BCMA have demonstrated promise in relapsed/refractory disease, even in patients with limited treatment options. As there are various mechanisms of action and modalities for currently available BCMA-targeted agents, pharmacists need to discern the nuances of each agent and differentiate between available therapies to ensure appropriate selection of an agent based on specific patient- and disease-related factors. This program will examine the economic burden of MM and will delve into approaches managed care pharmacists can use to facilitate pathways and ensure cost-effective care. The discussion will also address factors contributing to disparities in MM and the role of managed care professionals in ensuring equitable and timely access to emerging treatments.
Learning Objectives
- Explore the therapeutic landscape and the patient- and disease-specific factors that drive treatment decisions for the use of BCMA-directed therapies in multiple myeloma (MM).
- Examine the recent clinical updates and guideline-recommended use of BCMA-targeted therapies for MM.
- Investigate best practices in managed care to provide equitable access to BCMA-directed therapies in MM.
- Apply recent updates for BCMA-targeted treatments when developing eligibility criteria and making formulary decisions.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.comRegistration Link:
https://event.pharmacytimes.org/event/0fa6b151-ca92-4bf7-8cf5-3f22255e33cf/summary?tm=8abR3rC2SRixheWG5WvU53hofKfSJceAu4Xo_HuB0TY&locale=en-US
Wednesday, March 22, 2023| 6–8pm CT
- Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma| Location: 304BC
-
- Provider: Pharmacy Times Continuing Education™
- This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
- Continuing education credit available for managed care pharmacists
- Contact hours: 1.5
Program Description
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL). Despite standard-of-care immunotherapy, 30% to 40% of patients continue to experience relapse with poor prognosis or are refractory to frontline treatment. With limited approved treatment options in the relapsed/refractory (R/R) setting, there is an important opportunity for managed care pharmacists to remain informed about recently developed therapies, including chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates (ADCs), and the investigational T-cell engaging bispecific antibodies (BsAbs), as they develop clinical pathways for DLBCL. This program will review the distinctive features of CAR T-cell therapy that differentiate it from ADCs and BsAbs, with special consideration for patient-specific factors that influence treatment selection. Managed care strategies to address health care disparities, access to care, and affordability will also be discussed.
Learning Objectives
- Compare the role of antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapy in the treatment paradigm of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and the emerging data on the utility of bispecific antibodies.
- Examine recent clinical data, current treatment guidelines, and their impact to formulary decisions for the treatment of R/R DLBCL.
- Explore opportunities to facilitate access and improve safety and supportive care for patients with R/R DLBCL through appropriate assessment of patients and their treatment regimens.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.comRegistration Link:
https://event.pharmacytimes.org/event/0fa6b151-ca92-4bf7-8cf5-3f22255e33cf/summary?tm=8abR3rC2SRixheWG5WvU53hofKfSJceAu4Xo_HuB0TY&locale=en-US - ManagedCareCGM.com Presents: Innovations in rtCGM to Improve Clinical Outcomes in Diabetes| Location: 303BC
-
- Provided by Impact Education, LLC and Medical Education Resources
- Supported by Dexcom, Inc.
- CPE/CME/CNE Credit Available
- Contact hours: 1.5
Program Description
Continuous glucose monitoring (CGM) offers immediate assessment of glucose levels and trends. CGMs can provide alerts when glucose levels exceed low or high thresholds or are changing rapidly, allowing patients to adjust insulin dosing or consume carbohydrates to minimize the risk of hypoglycemia. CGM technology also offers key insights for clinicians—including pharmacy professionals—and offers an opportunity for enhanced patient engagement and lifestyle modification. Professional organizations continue to expand recommendations supporting CGM use in patient care protocols in a broader population of patients with type 1, type 2, and gestational diabetes. Current guidelines, emerging clinical evidence, and a presentation of case studies will illustrate the opportunity for real-time CGM (rtCGM) to measurably improve care quality and outcomes for patients with diabetes. Pertinent to managed care decision makers, the discussion will include pharmacy benefit design to improve patient access to rtCGM.
Learning Objectives
- Assess clinical evidence and professional society guidelines for CGM systems in patients with type 1 or type 2 diabetes.
- Characterize the impact of rtCGM on clinical measures of diabetes care.
- Implement medical and pharmacy benefit design strategies to support appropriate access to rtCGM and develop evidence-based clinical criteria.
Program Manager
Allison Hartless
Impact Education, LLC.
allison.hartless@impactedu.netRegistration Link:
https://www.managedcarecgm.com/amcp2023
Thursday, March 23, 2023| 6–8am CT
- Management of Eosinophilic Esophagitis: Opportunities for Pharmacists to Increase Awareness and Optimize Care| Location 304BC
-
- Provider: ProCE
- Supported by Regeneron Pharmaceuticals, Inc. and Sanofi
- Continuing education credit available for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with eosinophilic esophagitis, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice
- Contact hours: 1.5
Program Description
Eosinophilic esophagitis (EoE) is a chronic immune/antigen-mediated disorder of the esophagus that is relatively unfamiliar to many healthcare professionals (HCPs). It is characterized by esophageal dysfunction and eosinophil-predominant inflammation and affects a disproportionate number of children and young adults. EoE remains underrecognized and undertreated despite its increasing prevalence. With no cure currently available, HCPs must stay abreast of the latest clinical data on emerging therapies that target the underlying triggers of this disease. Moreover, patients will face ongoing symptoms, evaluation, treatment, and disease management strategies as they transition into adulthood. Therefore, a planned transition of care from the pediatric to adult team must be in place, but established protocols are lacking. As HCPs are seeing an increasing number of patients with EoE, there is a significant need for education on early recognition, prompt treatment, and effective transitions of care for patients with EoE. As medication therapy experts, pharmacists play an important role in pharmacotherapy management and patient education. Pharmacists are routinely involved in direct patient care and collaborate with other HCPs to address medication therapy selection and optimization, manage adverse events, and provide patient and caregiver counseling. Furthermore, managed care pharmacists are responsible for the development and use of a broad and diversified range of clinical and quality-oriented drug management services to ensure patient-centered optimization of medication therapy. Managed care pharmacists use best practices to offer quality care and cost-effective medication coverage to patients, payers, employers, and the government. This program will prepare pharmacists to effectively collaborate in the management of EoE to improve patient outcomes.
Learning Objectives
- Describe the pathophysiology and burden of disease in EoE
- Evaluate current and emerging therapies based on their impact on disease outcomes in patients with EoE
- Identify strategies for coordinating with the multidisciplinary team to improve health-related quality of life and outcomes for patients with EoE
- Discuss the role of the pharmacist in EoE disease management, including in transitions of care
Program Manager
Kerry Rosa
ProCE
krosa@practicingclinicians.com - Using Real-World Evidence to Achieve High Quality Care that Improves Payer Outcomes for Multiple Sclerosis| Location:303BC
-
- Provider by Impact Education, LLC and Partners for Advancing Clinical Education (PACE)
- Supported by Sanofi
- CME/CPE Credit Available
- Contact hours: 1.5
Program Description
Multiple sclerosis (MS) onset typically occurs in the prime of life, between the ages of 20 and 40 years, with women affected approximately twice as often as men. MS is the leading cause of non-traumatic disability in young adults. This symposium highlights opportunities for managed care and specialty pharmacy professionals to enhance disease state knowledge and administrative competencies to manage health plan patients with MS resulting in optimal clinical and economic outcomes.
Learning Objectives
- Review the impact of health equity and the unique challenges presented by MS in diverse patient populations
- Assess how current and emerging therapies impact disease control in diverse patient populations and their fit into the MS treatment algorithm
- Interpret the value of real-world evidence to inform appropriate access and reimbursement decisions for patients with MS
- Illustrate collaborative treatment optimization approaches to balance costs with improved outcomes for the management of MS
Program Manager
Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.netRegistration Link:
http://www.impactedu.net/msamcp2023
Thursday, March 23, 2023 | 6–8pm CT
- New Evidence in Worsening Heart Failure: Examining Implications for Managed Care| Location: 303BC
-
- Provider PRIME Education
- Supported by Cytokinetics, Inc.
- Continuing education credit available for Medical and pharmacy directors, pharmacists, medication therapy management (MTM) nurses working in managed care organizations (ACPE, ACCME, AAPA, AANP, ANCC)
- Contact hours: 1.25
Program Description
Worsening heart failure has significant economic impact with high rates of hospitalization, morbidity, and mortality. Join this satellite symposium in-person or virtually to hear leading experts discuss the latest clinical evidence on new and emerging treatments for worsening heart failure and applications for managed care decision-making to improve outcomes for patients with this complex disease.
Don't miss this opportunity to:
- See NEW real-world survey data from managed care professionals
- Gain real-world insights into unmet patient needs, health disparities, and treatment considerations for worsening heart failure
- Engage in live Q&A with renowned heart failure experts
Learning Objectives
- Examine the impact of worsening heart failure (WHF) on healthcare utilization and patient outcomes
- Assess data related to real-world adherence to guideline-directed medical therapy (GDMT) that drive healthcare disparities in heart failure
- Differentiate new and emerging therapies for HF based on mechanism of action, safety, efficacy, and cost-effectiveness data
- Align managed care decision-making with current evidence, treatment guidelines, and patient factors to ensure appropriate patient selection and equitable access to therapies for heart failure
Program Manager
Jill Friedman PRIME Education
j.friedman@primeinc.orgRegistration Link:
https://primeinc.org/43LV221?utm_source=AMCP&utm_medium=webtxt&utm_id=43LV221 - The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics| Location: 304BC
-
- Provider AcademicCME
- Supported by Pfizer Inc.
- Continuing education credit available for Pharmacists, managed care specialists, gastroenterologists, rheumatologists, nurses, and other health care professionals involved in the treatment of patients with inflammatory conditions, as well as patients with these conditions.
- Contact hours: 1.5
Program Description
While biosimilar therapeutics have been widely available for some time for the treatment inflammatory conditions, many pharmacists, managed care professionals, and other healthcare providers have not had a recent opportunity to investigate data showing the interchangeable safety and efficacy alignment between approved biosimilar therapeutics and their less accessible referent medications. In addition to interchangeability, concepts involving extrapolation and the shifting of a treatment plan to include biosimilar equivalents may not have made clear inroads into the daily practice of those involved in medication distribution and formulary management. A clinical update on these concepts, specifically regarding biosimilars for inflammatory conditions, may reduce or remove serious barriers to care affecting patients with inflammatory bowel disease, RA, psoriatic arthritis, and psoriasis. Pharmacists, managed care professionals, and other healthcare providers should have an opportunity to analyze clinical trial data for new and emerging biosimilar therapies to improve care for all patients with moderate to severely active inflammatory conditions. Accounting for the complex needs of individuals with these conditions, including socioeconomic needs affecting healthcare access, can improve outcomes through the application of customized medicine that contributes to the care of the whole patient. AcademicCME has identified a need for educational programs that can provide this guidance.
Learning Objectives
- Review current on the developmental and clinical trial process of biosimilar therapies and recent advances in the use of biosimilars to treat inflammatory bowel disease and rheumatological disorders.
- Analyze recent clinical trial data and review practical approaches for the use of biosimilars, including interchangeability and switching.
- Develop strategies to communicate with the interprofessional team and educate patients on biosimilars, including issues of varying patient perceptions.
Program Manager
Nicole McMenamin
AcademicCME
nmcmenamin@academiccme.comRegistration Link:
Friday, March 24, 2023| 6–8am CT
- Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia| Location: 304BC
-
- Provider: Pharmacy Times Continuing Education™
- This activity has been supported by an educational grant from Bristol Myers Squibb.
- Continuing education credit available for managed care pharmacists
- Contact hours: 1.5
Program Description
The treatment armamentarium in acute myeloid leukemia (AML) has benefitted from recent approvals, expanded indications, and continued investigation of maintenance therapy regimens for patients. Unfortunately, only 5% to 15% of patients with AML older than 60 years attain disease cure. Treatment decisions for older patients with AML are complex due to various patient- and disease-specific challenges that can affect their ability to tolerate therapy. The advent of recently approved agents for AML has brought increases in pharmacy-related costs and greater financial burden for patients. Managed care professionals have an important responsibility to implement cost reduction approaches within the multidisciplinary care team to increase the efficiency and timeliness of therapy initiation for older patients with AML. This program will review recent clinical data for investigational maintenance regimens in the treatment of AML as well as cytogenetic and molecular abnormalities, patient preference and contraindications, clinical guidelines, benefits and toxicities of treatments, and cost management strategies that influence therapy selection and sequencing in older patients with AML.
Learning Objectives
- Examine guideline recommendations and recent literature to individualize induction regimens for older patients with acute myeloid leukemia (AML).
- Identify patients most likely to benefit from maintenance therapy based on patient- and disease-specific factors.
- Investigate opportunities within the managed care role to contribute to individualized treatment approaches in older patients with AML as well as multidisciplinary care strategies for optimal cost management and improved outcomes.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.comRegistration Link:
https://event.pharmacytimes.org/event/0fa6b151-ca92-4bf7-8cf5-3f22255e33cf/summary?tm=8abR3rC2SRixheWG5WvU53hofKfSJceAu4Xo_HuB0TY&locale=en-US - Opioid Analgesic Therapy for Chronic Pain: Defining Current Therapeutic Use | Location: 303BC
-
- Provider CPE, CME
- Supported by Collegium Pharmaceuticals
- Continuing education credit available for Pharmacists, Anesthesiologists, Primary care physicians
- Contact hours: 1.5
Program Description
This program is a 90-minute symposium led by expert faculty to increase awareness among clinicians regarding when and for what types of chronic pain conditions opioid analgesics should be considered; strategies for mitigating adverse events associated with the use of opioid analgesics for the management of chronic pain
Learning Objectives
- Increased knowledge regarding the o Clinical data on inappropriate prescribing practices associated with opioid analgesics o Clinical data on opioids analgesics with features designed to reduce the occurrence of adverse events
- Greater confidence in their ability to o Identify patients with chronic pain who are appropriate candidates for opioid analgesic therapy
Program Manager
Kelly Connors
Medscape Education
kconnors@medscapelive.comRegistration Link: